Syndax Pharmaceuticals, Inc.SNDXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank49
3Y CAGR-57.8%
5Y CAGR-36.7%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-57.8%/yr
vs -13.7%/yr prior
5Y CAGR
-36.7%/yr
Recent deceleration
Acceleration
-44.2pp
Decelerating
Percentile
P49
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.48% |
| Q3 2025 | 19.66% |
| Q2 2025 | 7.74% |
| Q1 2025 | -65.82% |
| Q4 2024 | 7.92% |
| Q3 2024 | 13.01% |
| Q2 2024 | 14.25% |
| Q1 2024 | -102.06% |
| Q4 2023 | 7.40% |
| Q3 2023 | -26.24% |
| Q2 2023 | 9.83% |
| Q1 2023 | -71.35% |
| Q4 2022 | 19.79% |
| Q3 2022 | 29.18% |
| Q2 2022 | 3.88% |
| Q1 2022 | -141.64% |
| Q4 2021 | 503.74% |
| Q3 2021 | -3.74% |
| Q2 2021 | -6.45% |
| Q1 2021 | -44.51% |
| Q4 2020 | 14.57% |
| Q3 2020 | 14.53% |
| Q2 2020 | -34.42% |
| Q1 2020 | -25.13% |
| Q4 2019 | -49.22% |
| Q3 2019 | 31.90% |
| Q2 2019 | 25.58% |
| Q1 2019 | -11.89% |
| Q4 2018 | 18.55% |
| Q3 2018 | -21.92% |
| Q2 2018 | 23.76% |
| Q1 2018 | -56.19% |
| Q4 2017 | -24.96% |
| Q3 2017 | 13.72% |
| Q2 2017 | 6.85% |
| Q1 2017 | -21.62% |
| Q4 2016 | 9.01% |
| Q3 2016 | -66.15% |
| Q2 2016 | -7.61% |
| Q1 2016 | -49.08% |